SANA | Sana Biotechnology, Inc. Stock Overview

(Stock Exchange: NASDAQ)

Day's Range	2.3700 - 2.7300
52 Week Range	2.2900 - 12.00
Beta	1.66
Implied Volatility	219.93%
IV Rank	41.11%
Day's Volume	1,815,421
Average Volume	1,429,779
Shares Outstanding	223,269,000
Market Cap	582,732,090
Sector	Healthcare
Industry	Biotechnology
IPO Date	2021-02-04

Valuation
Profitability
Growth
Health
P/E Ratio	-1.86
Forward P/E Ratio	N/A
EPS	-1.40
1YR Price Target	N/A
Dividend Yield	N/A
Dividend Per Share	N/A
Dividend ExDate	N/A
Dividend PayDate	N/A
Employees	328
Country	USA
Website	SANA

Sana Biotechnology, Inc., a biotechnology company, focuses on utilizing engineered cells as medicines. The company develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system disorders, cardiovascular diseases, genetic disorders, and others. Its product candidates include SG295 and SG242 that target CD19+ cancer cells, including non-Hodgkin Lymphoma, chronic lymphocytic leukemia, and acute lymphoblastic leukemia; SG221 and SG239 for the treatment of multiple myeloma; and SG328 for ornithine transcarbamylase deficiency. It also develops SG418 for sickle cell disease and beta-thalassemia; SC291, a CD19 allogeneic T cell therapy; SC255 for multiple myeloma; SC451 for type I diabetes mellitus; and SC379 for secondary progressive multiple sclerosis, Pelizaeus-Merzbacher disease, and Huntington's disease. Sana Biotechnology, Inc. was formerly known as FD Therapeutics, Inc. and changed its name to Sana Biotechnology, Inc. in September 2018. The company was incorporated in 2018 and is headquartered in Seattle, Washington.

SANA's peers: ABSI, ADMA, ADPT, ALLK, ALLO, ATRA, BEAM, CGEM, CGEN, COGT, CRBU, EDIT, ERAS, EXAI, FATE, GBIO, GLUE, ITOS, LYEL, MDWD, NKTX, NRIX, NTLA, OLMA, RVMD, RXRX, LIFE, ZNTL, XFOR, GRTX, TERN, DAWN, HOOK, BPMC, KYMR, MRTX, AMLX, APLS, SEER, SWTX, TPST, VERV, PRME

*Chart delayed

Analyzing fundamentals for SANA we got that it has weak fundamentals where Valuation is considered to be significantly overvalued, Profitability is unacceptably poor, Growth is desperately bad and Health is very weak. For more detailed analysis please see SANA Fundamentals page.

Watching at SANA technicals we can see that long-term trend is bearish, the same as bearish middle-term trend, as well as bearish short-term trend. More technicals details can be found on SANA Technicals page.